Photodynamic Therapy: A Ray of Hope for Lung Cancer Treatment?
"Explore how photodynamic therapy (PDT) is revolutionizing lung cancer treatment, offering new hope for early and advanced stages."
The battle against lung cancer has seen significant advancements, especially with the introduction of the fiberoptic bronchoscope in 1965. This innovation paved the way for photodynamic medicine, harnessing light and photosensitizers to combat cancer. Now, with over three decades of experience, PDT is emerging as a promising solution.
This article explores the role of photodynamic diagnosis in lung cancers, including optical coherence tomography and the curative, palliative, and neoadjuvant applications of photodynamic therapy for both early and advanced stages of lung cancer. We will also look at how PDM (photodynamic medicine) is being used to treat peripheral early-stage lung tumors.
Early detection and precise localization of small lung tumors are key to improving treatment outcomes. Photodynamic therapy (PDT) offers a minimally invasive approach to treating these tumors. The goal of PDT is to provide curative treatment for superficial early-stage tumors, palliative care for advanced tumors, and neoadjuvant therapy to reduce the size of tumors before resection.
PDT’s Foundations and Use in Lung Cancer
Photodynamic therapy (PDT) has been used to treat lung cancer for nearly four decades and is now part of multidisciplinary lung cancer care. Its relatively low risk and ablative ability have made it an adjuvant treatment option for non-small cell lung cancer (NSCLC), including in combination with other therapies. PDT works through photosensitizers that produce reactive oxygen species when exposed to light at a corresponding absorption wavelength. The term “photodynamic” draws on the Greek words “phos,” meaning light, and “dynamis,” meaning force or power.
Fluorescence Bronchoscopy: Illuminating Lung Cancer Diagnosis
The fiberoptic bronchoscope significantly enhanced lung cancer diagnosis in 1965. However, early-stage superficial carcinomas often went undetected. In 1978, efforts began to develop a fluorescent bronchoscope to improve detection.
- Early clinical experience with PDD (photodynamic diagnosis) as an endobronchial tumor indicator was published in the 1980s and 1990s.
- Fluorescence imaging, using a hematoporphyrin derivative or Photofrin II (porfimer sodium) as a tumor marker, facilitated the bronchoscopic localization of early squamous cell carcinoma of the central tracheobronchial tree.
PDT Uses Across Lung Cancer Settings
A review of NSCLC describes PDT as an endobronchial treatment used to palliate symptoms in advanced disease with central airway obstruction and to treat occult central airway tumors identified through photodynamic diagnosis and other endoscopic methods. Another review reports that early-stage, superficial endobronchial lesions less than 1 cm thick can be treated effectively with external light sources. A study in dogs found that navigational bronchoscopy could successfully deliver PDT for peripheral lung cancers. A separate 2026 study describes a retrospective review of 23 patients treated at one center between April 2012 and December 2024, examining long-term outcomes for early and central airway lesions.
A Review of 5-ALA PDT in Dermatology
A review of photodynamic therapy in dermatology and venereology describes 5-aminolevulinic acid (5-ALA) PDT as a cancer treatment technique. The review characterizes 5-ALA PDT as safer and more effective than other forms of PDT and notes that its treatment indications have expanded in recent years. Its scope is dermatology and venereology, so the comparison reported here concerns that review’s context rather than a comparison of lung cancer treatments.
The Future of PDT: Emerging Strategies and Hope
PDT is a promising alternative for patients with advanced lung cancer. PDT can improve symptoms, maintain quality of life, decrease airway obstruction, and tumor stenosis, leading to better respiratory function. It can also resolve acute hemoptysis, poststenotic pneumonia, and enhance performance status.
Personalization and Timing
A 2026 review identifies patient-specific variation in tissue optical properties, photosensitizer pharmacokinetics, and tumor heterogeneity as challenges to tailoring PDT. A lung cancer review calls for research on ways to enhance and prolong PDT-associated immunity and to determine the timing of combination therapy. It also says that moving PDT earlier through improved standardized management and early detection remains an area for further exploration.
Challenges to Clinical Translation
A review describes phototherapy as a cancer treatment approach that has drawn attention for minimal side effects, spatial selectivity, and preservation of surrounding tissue. A separate review focuses on strategies and challenges for translating nanomedicine-mediated PDT into clinical use for lung cancer. It identifies light sources, photosensitizers, and surrounding substrates as PDT’s three core components.
Lung-Sparing Treatment in Reported Cases
A report describes PDT as a lung-sparing local treatment that may be an alternative for early-stage lung cancer patients with poor lung function or cancer at multiple sites. Another source notes that most historically reported PDT cases involved late-stage tumors obstructing the airway, while its discussion includes peripheral lung cancer. A 2022 case report describes a patient with invasive squamous cell carcinoma and multiple synchronous, radiologically silent endobronchial lesions who received stereotactic body radiation therapy followed by adjuvant PDT.
The incidence of adenocarcinoma and multiple primary lung cancers has increased over the past two decades. Adequate diagnostic and noninvasive therapeutic modalities are needed to manage them. CT screening for early detection of peripheral lung cancer has spread, and tiny cancers can be detected frequently.
PDT represents a promising treatment modality for patients with lung cancer. It serves as a definitive monotherapy for early-stage, centrally located non-small cell lung cancer and an effective palliative measure for improving many symptoms of advanced lung cancer. Emerging strategies for using PDT to treat early-stage peripheral lung cancer appear promising but require further study.